静脉维生素C治疗脓毒症或脓毒性休克患者结局的随机对照试验荟萃分析
该荟萃分析更新了静脉维生素C(IVVC)治疗脓毒症或脓毒性休克的随机对照试验证据,检索PubMed、EMBASE和ClinicalTrials.gov至2023年1月16日,纳入18项RCT共3364例患者。结果显示IVVC显著改善72-96小时SOFA评分较基线的变化(MD -0.62,95%CI -1.00至-0.25,p=0.001)并缩短血管加压药使用时间(MD -15.07,95%CI -21.59至-8.55,p<0.00001),但未改善短期死亡率(OR 0.89,95%CI 0.77至1.04,p=0.14),25-100 mg/kg/d亚组短期死亡率显著降低(OR 0.80,95%CI 0.65至0.97,p=0.03),且不良事件增加(OR 1.98,95%CI 1.06至3.68,p=0.03)。
要点
- 18项RCT共3364例脓毒症或脓毒性休克患者,IVVC组72-96小时SOFA评分较基线变化显著优于对照组(MD -0.62,95%CI -1.00至-0.25,p=0.001)。
- IVVC组血管加压药使用时间显著短于对照组(MD -15.07,95%CI -21.59至-8.55,p<0.00001)。
- IVVC未显著改善短期死亡率(OR 0.89,95%CI 0.77至1.04,p=0.14)。
- 25-100 mg/kg/d剂量亚组短期死亡率显著降低(OR 0.80,95%CI 0.65至0.97,p=0.03)。
- IVVC组不良事件显著增加(OR 1.98,95%CI 1.06至3.68,p=0.03)。
适用人群与场景
- 年龄≥18岁的脓毒症或脓毒性休克患者。
- 研究场景为随机对照试验,未限定具体急诊或ICU场景。
诊断标准与关键阈值
- 纳入标准:研究类型为RCT;患者≥18岁且诊断为脓毒症或脓毒性休克;干预为任何剂量的IVVC单药或联合硫胺素或氢化可的松,对照为标准治疗、无干预或安慰剂;RCT报告短期死亡率或SOFA评分。
处置流程与药物剂量
- IVVC为干预措施,剂量范围包括25-100 mg/kg/d亚组,具体给药途径为静脉给药,频次和疗程原文未写明。
- 对照为标准治疗、无干预或安慰剂。
研究设计与关键结果
- 研究类型为随机对照试验的荟萃分析,纳入18项RCT共3364例患者,检索PubMed、EMBASE和ClinicalTrials.gov至2023年1月16日。
- 主要终点:72-96小时SOFA评分较基线变化,IVVC组显著优于对照组(MD -0.62,95%CI -1.00至-0.25,p=0.001)。
- 次要终点:血管加压药使用时间,IVVC组显著短于对照组(MD -15.07,95%CI -21.59至-8.55,p<0.00001)。
- 短期死亡率:IVVC组与对照组无显著差异(OR 0.89,95%CI 0.77至1.04,p=0.14)。
- 亚组分析:25-100 mg/kg/d剂量亚组短期死亡率显著降低(OR 0.80,95%CI 0.65至0.97,p=0.03)。
- 不良事件:IVVC组显著增加(OR 1.98,95%CI 1.06至3.68,p=0.03)。
证据类型、等级与局限
- 证据类型:随机对照试验的荟萃分析。
对床旁实践的改变
- 在脓毒症或脓毒性休克成人患者中,静脉维生素C可能改善72-96小时SOFA评分变化并缩短血管加压药使用时间,但未显著降低短期死亡率且不良事件增加。
- 25-100 mg/kg/d剂量亚组与短期死亡率降低相关,但该亚组结果需结合整体证据解读。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: To update a meta-analysis of randomized controlled trials (RCTs) and further explore the outcome of IV vitamin C (IVVC) administration in sepsis or septic shock patients.
METHODS: This study is a meta-analysis of RCTs. The RCTs of vitamin C therapy in sepsis or septic shock were searched in PubMed, EMBASE and Clinical Trials.gov from inception to January 16, 2023. We registered the protocol with PROSPERO (CRD42022354875). The primary outcome was delta Sequential Organ Failure Assessment (SOFA) score at 72-96 h. Two reviewers independently assessed RCTs according to eligibility criteria: (1) study type: RCT; (2) patient population: patients ≥ 18 years with sepsis or septic shock; (3) intervention: IVVC at any doses as monotherapy or combined with thiamine or and hydrocortisone compared with standard of care, no intervention or placebo (defined as control group); (4) the RCT described short-term mortality or SOFA score. Then, two authors independently extracted related information from RCTs.
RESULTS: Eighteen RCTs (n = 3364 patients) were identified in this meta-analysis. There were significant effects in the delta SOFA score from baseline to 72-96 h (MD, - 0.62; 95% CI, - 1.00 to - 0.25; p = 0.001) and the duration of vasopressor use (MD, - 15.07; 95% CI, - 21.59 to - 8.55; p < 0.00001) with IVVC therapy. Treatment with IVVC was not shown to improve short-term mortality (OR, 0.89; 95% CI, 0.77 to 1.04; p = 0.14); nevertheless, dose at 25-100 mg/kg/d subgroup associated with a significant reduction in short-term mortality (OR, 0.80; 95% CI, 0.65 to 0.97; p = 0.03). An increase adverse event was observed in IVVC therapy (OR, 1.98; 95% CI, 1.06 to 3.68; p = 0.03).
CONCLUSION: In this meta-analysis, IVVC in sepsis or septic shock patients significantly improved delta SOFA score and reduced the duration of vasopressor use, whereas it was not associated with reduction in short-term mortality and had higher adverse events.
参考来源
- Liang B, Su J, Shao H, et al. The outcome of IV vitamin C therapy in patients with sepsis or septic shock: a meta-analysis of randomized controlled trials. Crit Care. 2023. PMID: 36915173. doi:10.1186/s13054-023-04392-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。